Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
BKM120 is a newly discovered drug that has been used in other research studies. Information
from those other research studies suggests that BKM120 may help to slow or stop the growth of
malignant gliomas. The purpose of this study is to see how well BKM120 works in patients with
malignant gliomas. Patients on this study will be treated in two groups: patients who are
going to receive surgery and those who will not receive surgery. This study is trying to
determine how effective BKM120 is in stopping cancer cells from growing. For patients
receiving surgery the research will also try to determine if an effective level of BKM120 can
penetrate the brain before surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Brigham and Women's Hospital M.D. Anderson Cancer Center Massachusetts General Hospital Memorial Sloan Kettering Cancer Center Novartis Pharmaceuticals University of California, Los Angeles University of California, San Francisco University of Utah